Bespak addresses India’s biopharmaceutical drive for high value drug delivery products that differentiate generics, biobetters and biosimilars at CPHI India 2015
The company showcases the innovative Syrina 2.25 auto-injector that brings the flexibility to design a unique form factor and also the full Syrina platform accommodating multiple primary containers and high viscous, high volume injections.
Bespak is attending CPHI India 2015, and is utilising the internationally sponsored event to meet clients and to further highlight how its technology, in the field of combination products, auto-injectors and pen injectors, can best assist the complex requirements of India based biopharmaceutical companies. To date, Bespak has built-up and established strong customer relationships with many of the country’s leading biopharmaceutical companies for a range of products from Metered Dose Inhaler (MDI) valves, injectables, respiratory devices and more.
Steven Kaufman, Bespak’s Global Business Development Lead, commented: “India’s biopharmaceutical sector is on the look-out for highly innovative drug and delivery device solutions that provide a competitive edge for their products. Consequently, we are seeking to use this event to maintain our close relationships with our customers, whilst demonstrating how we can best service their needs with advanced drug delivery device technology that further increases value by helping to differentiate their generic, biobetter and biosimilar drugs.”
He continued: “For example, we will be demonstrating how our latest addition to the Syrina product range, the Syrina 2.25, which utilises cutting edge drug delivery technology, brings the flexibility of being able to design a truly unique form factor to the market.”
Syrina 2.25 utilises the standard 2.25ml pre-filled syringe, based on Bespak’s proprietary VapourSoft™ technology and will also be available in a 1-mlLversion.
The VapourSoft powerpack system helps overcome issues seen in spring-based auto-injectors. Based on proven valve technology, a small novel container of liquefied gas serves as a new power source. The propellant, when released, provides sufficient energy, in the form of a pressurised vapour, to power drug delivery and other functions. The consistent delivery performance across the Syrina product range gives researchers and biopharmaceutical companies the ability to use Syrina with VapourSoft at a very early stage of development. Several variations of the devices are available for clinical trials with a range of industrial designs being considered for the body of the auto-injectors to best suit patient needs. The Syrina auto injector with VapourSoft platform is proven to accommodate multiple primary containers, as well as high viscosity and high volume injections.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance